Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 09 Feb 2016 New trial record